Azoulay Salomon 4

What Happened

• Salomon Azoulay, Chief Medical Officer of MBX Biosciences (MBX), received awards on 2026-02-02 totaling 85,000 shares: 15,000 restricted stock units (RSUs) and a 70,000-share derivative award. Both awards were reported as granted at $0.00 (code A on the Form 4).
• These are compensation grants (not open-market purchases or sales). The filing shows acquisition via award; no immediate cash proceeds or sales are reported.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 3, 2026 (timely filing).
• Price: $0.00 for both awards (standard for equity compensation grants).
• Vesting:
  • 15,000 RSUs vest in equal quarterly installments over four years (footnote F1).
  • 70,000 derivative award vests in 48 equal monthly installments beginning March 2, 2026 (footnote F2).
• Shares owned after the transaction: Not specified in the provided filing extract.
• Transaction code: A = Award/Grant. No 10b5-1, tax-withholding, or late-filing flags noted in the filing excerpt.

Context

• RSUs convert to actual shares as they vest; the derivative award appears to be an option-like award that vests monthly — neither represents an immediate open-market buy or sale.
• Because grants are compensation, they don't necessarily signal insider buying interest; their value depends on MBX's future share price at vesting/exercise.